Trial Profile

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 11 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deutetrabenazine (Primary)
Indications Chorea; Huntington's disease
Focus Therapeutic Use

Most Recent Events

07 Nov 2024 Planned End Date changed from 1 Apr 2025 to 1 Apr 2026.
07 Nov 2024 Planned primary completion date changed from 30 Aug 2024 to 1 Aug 2025.
18 Apr 2024 Results (n=8) assessing effect of deutetrabenazine on functional speech production and gait dynamics in individuals with Huntingtons Disease presented at the 76th Annual Meeting of the American Academy of Neurology 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com